Pharmaceuticals

After a major trial failure tanked its stock, Rezolute pins its hopes on a second drug program and a crucial FDA meeting to chart a path forward.

With a promising heart failure drug in trials, the biotech aims to woo investors at the Oppenheimer conference to fund its attack on age-related diseases.

Celcuity adds Seagen commercial veteran Charles Romp to its board, a strategic move signaling its pivot from R&D to market readiness for gedatolisib.

DifGen Pharmaceuticals' new FDA-approved generic eye drop is only the second of its kind, promising to increase competition and lower costs for patients.

Texas Athletics and supplement brand Humann partner to turn basketball games into a live lesson on heart health, blending science, sports, and marketing.

In a landmark move, the FDA has removed major risk warnings from hormone therapy drugs, signaling a new era for women's health after decades of fear.

Dr. Ginna Laport, a leader from both pharma and academia, joins NMDP to spearhead a new initiative aimed at making life-saving cell therapies a reality for more patients.

With strong Phase 1 data and key FDA backing, Trethera's TRE-515 is advancing as a 'pipeline-in-a-product' for a wide range of diseases.

With a new chair from Genmab and a board of industry titans, BioNJ is poised to bolster New Jersey's status as a global biotech powerhouse.

CRB appoints veteran John R. Lupa, Jr. to spearhead national construction, a strategic move to dominate the booming life sciences and food facility market.

A new partnership embeds microchips into drug vials, aiming to revolutionize DSCSA compliance and create a tamper-proof pharmaceutical supply chain.

A new oral drug, IMSB301, offers hope for Aicardi Goutières Syndrome, a devastating rare disease with no cure, in a pivotal new clinical trial.

Clinical-stage biotech BioVie announces its novel anti-inflammatory drug, bezisterim, will be featured at a key psychiatric conference for its potential.

A new plant-derived drug shows promise in preventing prostate cancer and improving cholesterol, but the company faces significant financial hurdles ahead.

With promising new data for its cancer and obesity pipeline, Corbus Pharmaceuticals prepares for a crucial investor presentation at the Oppenheimer conference.

Compugen adds strategic powerhouse Dr. Michele Holcomb to its board, a move signaling its ambition to convert AI-driven discoveries into market value.

The Norwegian drugmaker posted all-time high revenue and EBITDA for 2025, signaling resilience and a strategic pivot to future growth beyond metformin.

A new drug, JIN-A02, shows early promise in overcoming resistance to common lung cancer therapies, even shrinking hard-to-treat brain metastases.

The vaccine maker posts record 2025 earnings on mpox demand but signals a strategic shift, prioritizing its travel vaccine portfolio over new R&D.

The French biopharma giant posts strong 2025 results and forecasts over 13% growth, fueled by a booming pipeline and unexpected market advantages.